Bavencio
Pfizer and Merck KGaA secure CHMP recommendation for Bavencio in Europe for first-line maintenance of urothelial carcinoma
December 14, 2020Sales and Marketing Bavencio, CHMP, EMA, Merck, Pfizer, pharma, urothelial carcinoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given its recommendation for …
MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme
September 3, 2020Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma
It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …
Bavencio Phase 3 head and neck cancer trial terminated
March 16, 2020Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure
Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …
Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma
January 7, 2020Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …
Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial
November 8, 2019Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod
March 1, 2018Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical
Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …
Merck KGaA and Pfizer’s Bavencio fails at Phase 3 in gastric cancer
November 28, 2017Research and Development Bavencio, Cancer, Merck, Pfizer, pharma
Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary …
Merck and Pfizer’s joint skin cancer drug gets EU approval
September 21, 2017Sales and Marketing Bavencio, Cancer, Merck, Pfizer, merkel cell carcinoma, pharma, pharmaceutical, skin canceer
Merck KGaA and Pfizer have announced that European authorisation of their jointly developed drug Bavencio (avelumab) as a monotherapy in …
Pfizer’s major drug doubles sales but overall revenue falls
August 1, 2017Research and Development, Sales and Marketing Bavencio, Pfizer, biotech, drugs, pharma, pharmaceutical, viagra
Pfizer revealed in its briefing on its second quarter financials that Ibrance, its breast cancer treatment, had grown in sales …
Merck KGaA and Pfizer enter the immunotherapy market with Bavencio
March 27, 2017Sales and Marketing Bavencio, Merck KGaA, Pfizer
Merck KGaA and Pfizer have won approval for the fourth immunotherapy treatment to enter the market, with an indication in …
